Cytochrome P450s and other enzymes in drug metabolism and toxicity

The cytochrome P450 (P450) enzymes are the major catalysts involved in the metabolism of drugs. bioavailability and toxicity are 2 of the most common barriers in drug development today, and P450 and the conjugation enzymes can influence these effects. The toxicity of drugs can be considered in 5 contexts: on-target toxicity, hypersensitivity and immunological reactions, off-target pharmacology, bioactivation to reactive intermediates, and idiosyncratic drug reactions. the chemistry of bioactivation is reasonably well understood, but the mechanisms underlying biological responses are not. In the article we consider what fraction of drug toxicity actually involves metabolism, and we examine how species and human interindividual variations affect pharmacokinetics and toxicity.

[1]  D. Jollow,et al.  Acetaminophen structure-toxicity studies: in vivo covalent binding of a nonhepatotoxic analog, 3-hydroxyacetanilide. , 1990, Toxicology and applied pharmacology.

[2]  J. Hedges,et al.  Use of terfenadine and contraindicated drugs. , 1996, JAMA.

[3]  F. Guengerich,et al.  Microsomal oxidation of tribromoethylene and reactions of tribromoethylene oxide. , 2002, Chemical research in toxicology.

[4]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[5]  W. H. Schaefer,et al.  Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. , 2004, Toxicology and applied pharmacology.

[6]  R. D. Stewart,et al.  Experimental human exposure to trichloroethylene. , 1970, Archives of environmental health.

[7]  H. Cui,et al.  Liver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene , 2003, Journal of Biological Chemistry.

[8]  Defeng Wu,et al.  CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. , 2001, Free radical biology & medicine.

[9]  F Peter Guengerich,et al.  Function of human cytochrome P450s: characterization of the orphans. , 2005, Biochemical and biophysical research communications.

[10]  C. Wolf,et al.  Inactivation of the Hepatic Cytochrome P450 System by Conditional Deletion of Hepatic Cytochrome P450 Reductase* , 2003, The Journal of Biological Chemistry.

[11]  Guengerich Fp,et al.  Reaction of aflatoxin B1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. , 1997 .

[12]  J. Fahey,et al.  Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Borzelleca.  Paracelsus: herald of modern toxicology. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[14]  P. Beaune,et al.  Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. , 1990, The Journal of clinical investigation.

[15]  B B Brodie,et al.  Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. , 1973, The Journal of pharmacology and experimental therapeutics.

[16]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[17]  Kevin M Williams,et al.  Reaction of aflatoxin B(1) oxidation products with lysine. , 2002, Chemical research in toxicology.

[18]  J. Miller,et al.  Historical perspectives on conjugation-dependent bioactivation of foreign compounds. , 1994, Advances in pharmacology.

[19]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[20]  A. Y. Lu,et al.  Metabolism of benzo(a)pyrene and benzo (a)pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. , 1976, The Journal of biological chemistry.

[21]  J E Huff,et al.  New evidence on the old problems of trichloroethylene. , 1971, IMS, Industrial medicine and surgery.

[22]  S D Nelson,et al.  The microsomal metabolism and site of covalent binding to protein of 3'-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen. , 1984, Drug metabolism and disposition: the biological fate of chemicals.

[23]  K. Kilburn.  Is Neurotoxicity Associated with Environmental Trichloroethylene (TCE)? , 2002, Archives of environmental health.

[24]  F. Guengerich,et al.  Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. , 2001, Chemical research in toxicology.

[25]  A. Burlingame,et al.  Identification of the Hepatic Protein Targets of Reactive Metabolites of Acetaminophen in Vivo in Mice Using Two-dimensional Gel Electrophoresis and Mass Spectrometry* , 1998, The Journal of Biological Chemistry.

[26]  T. Baillie,et al.  Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. , 2004, Chemical research in toxicology.

[27]  Huff Je,et al.  New evidence on the old problems of trichloroethylene. , 1971 .

[28]  A. Kalgutkar,et al.  Minimising the potential for metabolic activation in drug discovery , 2005, Expert opinion on drug metabolism & toxicology.

[29]  F. Guengerich,et al.  Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[30]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[31]  Daniel C. Liebler,et al.  Elucidating mechanisms of drug-induced toxicity , 2005, Nature Reviews Drug Discovery.

[32]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[33]  F. Guengerich,et al.  Tetrachloroethylene oxide: hydrolytic products and reactions with phosphate and lysine. , 2002, Chemical research in toxicology.

[34]  L. Wienkers,et al.  Predicting in vivo drug interactions from in vitro drug discovery data , 2005, Nature Reviews Drug Discovery.

[35]  F. Guengerich.  Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. , 2003, Archives of biochemistry and biophysics.

[36]  J. Uetrecht,et al.  New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. , 1999, Chemical research in toxicology.

[37]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[38]  J. Miners,et al.  “Phase I and Phase II” Drug Metabolism: Terminology that we Should Phase Out? , 2005, Drug metabolism reviews.

[39]  PROFILES IN TOXICOLOGY , 2000 .

[40]  R H Reitz,et al.  In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. , 1989, Toxicology and applied pharmacology.

[41]  F. Guengerich,et al.  Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome P450 1A2. , 1998, Chemical research in toxicology.

[42]  F Peter Guengerich,et al.  Principles of covalent binding of reactive metabolites and examples of activation of bis-electrophiles by conjugation. , 2005, Archives of biochemistry and biophysics.

[43]  B. Ames,et al.  Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[45]  F. Guengerich,et al.  KINETICS AND MECHANISM OF HYDROLYSIS OF AFLATOXIN B1 EXO-8,9-EPOXIDE AND REARRANGEMENT OF THE DIHYDRODIOL , 1996 .

[46]  B. Ames,et al.  Induction of cytochrome P4501A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin or indolo(3,2-b)carbazole is associated with oxidative DNA damage. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. van Bladeren,et al.  Glutathione conjugate mediated toxicities. , 1990, Toxicology and applied pharmacology.

[48]  F. Guengerich,et al.  Reaction of trichloroethylene oxide with proteins and dna: instability of adducts and modulation of functions. , 2001, Chemical research in toxicology.

[49]  T. Colby,et al.  Progressive systemic sclerosis associated with exposure to trichloroethylene. , 1987, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[50]  F. Guengerich,et al.  Reaction of aflatoxin B1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[51]  F. Gonzalez,et al.  Targeted Disruption of the Microsomal Epoxide Hydrolase Gene , 1999, The Journal of Biological Chemistry.

[52]  F. Guengerich,et al.  Activation of dihaloalkanes by thiol-dependent mechanisms. , 2003, Journal of biochemistry and molecular biology.

[53]  Miller Re,et al.  Oxidation of trichloroethylene by liver microsomal cytochrome P-450: evidence for chlorine migration in a transition state not involving trichloroethylene oxide. , 1982 .

[54]  F. Guengerich,et al.  Human cytochrome P-450 enzymes. , 1992, Life sciences.

[55]  M. Williams-Johnson,et al.  Toxicological profile for trichloroethylene , 1997 .

[56]  J. Dorne,et al.  Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[57]  D. Kupfer,et al.  Metabolic activation of pesticides with proestrogenic activity. , 1987, Federation proceedings.

[58]  F. Guengerich,et al.  Mechanism of Aqueous Decomposition of Trichloroethylene Oxide , 1999 .

[59]  F Peter Guengerich,et al.  Cytochrome P450: What Have We Learned and What Are the Future Issues? , 2004, Drug metabolism reviews.

[60]  K Walton,et al.  Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[61]  Ulrich Klotz,et al.  Inhibition of Terfenadine Metabolism , 1994, Clinical pharmacokinetics.